SNRI ‘Shows Promise’ for Comorbid ADHD, PTSD
Atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), may improve outcomes for patients with both attention-deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD), new research suggests. A pilot trial of veterans with comorbid ADHD/PTSD showed that atomoxetine significantly reduced ADHD symptoms and moderately improved PTSD treatment outcomes and quality of life in comparison with placebo.
Other Articles in this Edition
SNRI ‘Shows Promise’ for Comorbid ADHD, PTSD
Navigating New Challenges in the Management of ADHD
Dueling Diagnoses: Do You Have ADHD, OCD, or Both?
Sugar and ADHD: What’s the Connection?
Q&A: Bipolar Disorder and ADHD Co-Occurrence Rates Indicate Need For Screenings
Hypertensive Disorders of Pregnancy Tied to Child Neurodevelopment
Mary Rooney, PhD: The Challenges of ADHD During a Pandemic
Neurodiversity offers huge pool of untapped finance talent
What to expect from ADHD in relationships
It’s time to stop saying words like ‘Schitzo’ and phrases like ‘I’m so OCD.’ Here’s why.